APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cyclophosphamide Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cyclophosphamide Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025195 pages

Choose your research edition.

Industry ResearchCyclophosphamide Injection Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Cyclophosphamide Injection Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Cyclophosphamide Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cyclophosphamide Injection Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Cyclophosphamide Injection Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Cyclophosphamide Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cyclophosphamide Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cyclophosphamide Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cyclophosphamide Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cyclophosphamide Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cyclophosphamide Injection include Amneal Pharmaceuticals, Athenex, Aurobindo Pharma, Getwell Oncology, GLS Pharma, Ingenus, NorthStar Rx LLC, Zydus Cadila and Baxter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cyclophosphamide Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cyclophosphamide Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cyclophosphamide Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cyclophosphamide Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Cyclophosphamide Injection Segment by Company

Amneal Pharmaceuticals

Athenex

Aurobindo Pharma

Getwell Oncology

GLS Pharma

Ingenus

NorthStar Rx LLC

Zydus Cadila

Baxter

Jiangsu Hengrui Medicine

Pfizer

Novartis

Cyclophosphamide Injection Segment by Type

High-Dose

Low-Dose

Cyclophosphamide Injection Segment by Application

AL Amyloidosis

Cancer

Autoimmune Diseases

Others

Cyclophosphamide Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyclophosphamide Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cyclophosphamide Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyclophosphamide Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cyclophosphamide Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cyclophosphamide Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cyclophosphamide Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cyclophosphamide Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cyclophosphamide Injection Industry Trends Table 2. Cyclophosphamide Injection Industry Drivers Table 3. Cyclophosphamide Injection Industry Opportunities and Challenges Table 4. Cyclophosphamide Injection Industry Restraints Table 5. Global Cyclophosphamide Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cyclophosphamide Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cyclophosphamide Injection Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Cyclophosphamide Injection Sales Market Share by Manufacturers Table 9. Global Cyclophosphamide Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cyclophosphamide Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cyclophosphamide Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cyclophosphamide Injection Manufacturers, Product Type & Application Table 13. Global Cyclophosphamide Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cyclophosphamide Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of High-Dose Table 17. Major Manufacturers of Low-Dose Table 18. Global Cyclophosphamide Injection Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Cyclophosphamide Injection Sales by Type (2021-2026) & (K Units) Table 20. Global Cyclophosphamide Injection Sales by Type (2027-2032) & (K Units) Table 21. Global Cyclophosphamide Injection Sales Market Share by Type (2021-2026) Table 22. Global Cyclophosphamide Injection Sales Market Share by Type (2027-2032) Table 23. Global Cyclophosphamide Injection Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Cyclophosphamide Injection Revenue by Type (2021-2026) & (K Units) Table 25. Global Cyclophosphamide Injection Revenue by Type (2027-2032) & (K Units) Table 26. Global Cyclophosphamide Injection Revenue Market Share by Type (2021-2026) Table 27. Global Cyclophosphamide Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of AL Amyloidosis Table 29. Major Manufacturers of Cancer Table 30. Major Manufacturers of Autoimmune Diseases Table 31. Major Manufacturers of Others Table 32. Global Cyclophosphamide Injection Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Cyclophosphamide Injection Sales by Application (2021-2026) & (K Units) Table 34. Global Cyclophosphamide Injection Sales by Application (2027-2032) & (K Units) Table 35. Global Cyclophosphamide Injection Sales Market Share by Application (2021-2026) Table 36. Global Cyclophosphamide Injection Sales Market Share by Application (2027-2032) Table 37. Global Cyclophosphamide Injection Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Cyclophosphamide Injection Revenue by Application (2021-2026) & (K Units) Table 39. Global Cyclophosphamide Injection Revenue by Application (2027-2032) & (K Units) Table 40. Global Cyclophosphamide Injection Revenue Market Share by Application (2021-2026) Table 41. Global Cyclophosphamide Injection Revenue Market Share by Application (2027-2032) Table 42. Global Cyclophosphamide Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Cyclophosphamide Injection Sales by Region (2021-2026) & (K Units) Table 44. Global Cyclophosphamide Injection Sales Market Share by Region (2021-2026) Table 45. Global Cyclophosphamide Injection Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Cyclophosphamide Injection Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Cyclophosphamide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Cyclophosphamide Injection Sales by Country (2021-2026) & (K Units) Table 49. North America Cyclophosphamide Injection Sales by Country (2027-2032) & (K Units) Table 50. Europe Cyclophosphamide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Cyclophosphamide Injection Sales by Country (2021-2026) & (K Units) Table 52. Europe Cyclophosphamide Injection Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Cyclophosphamide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Cyclophosphamide Injection Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Cyclophosphamide Injection Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Cyclophosphamide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Cyclophosphamide Injection Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Cyclophosphamide Injection Sales by Country (2027-2032) & (K Units) Table 59. Global Cyclophosphamide Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Cyclophosphamide Injection Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Cyclophosphamide Injection Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Cyclophosphamide Injection Revenue Market Share by Region (2021-2026) Table 63. Global Cyclophosphamide Injection Revenue Market Share by Region (2027-2032) Table 64. Amneal Pharmaceuticals Company Information Table 65. Amneal Pharmaceuticals Business Overview Table 66. Amneal Pharmaceuticals Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Amneal Pharmaceuticals Cyclophosphamide Injection Product Portfolio Table 68. Amneal Pharmaceuticals Recent Development Table 69. Athenex Company Information Table 70. Athenex Business Overview Table 71. Athenex Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Athenex Cyclophosphamide Injection Product Portfolio Table 73. Athenex Recent Development Table 74. Aurobindo Pharma Company Information Table 75. Aurobindo Pharma Business Overview Table 76. Aurobindo Pharma Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Aurobindo Pharma Cyclophosphamide Injection Product Portfolio Table 78. Aurobindo Pharma Recent Development Table 79. Getwell Oncology Company Information Table 80. Getwell Oncology Business Overview Table 81. Getwell Oncology Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Getwell Oncology Cyclophosphamide Injection Product Portfolio Table 83. Getwell Oncology Recent Development Table 84. GLS Pharma Company Information Table 85. GLS Pharma Business Overview Table 86. GLS Pharma Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GLS Pharma Cyclophosphamide Injection Product Portfolio Table 88. GLS Pharma Recent Development Table 89. Ingenus Company Information Table 90. Ingenus Business Overview Table 91. Ingenus Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Ingenus Cyclophosphamide Injection Product Portfolio Table 93. Ingenus Recent Development Table 94. NorthStar Rx LLC Company Information Table 95. NorthStar Rx LLC Business Overview Table 96. NorthStar Rx LLC Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. NorthStar Rx LLC Cyclophosphamide Injection Product Portfolio Table 98. NorthStar Rx LLC Recent Development Table 99. Zydus Cadila Company Information Table 100. Zydus Cadila Business Overview Table 101. Zydus Cadila Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Zydus Cadila Cyclophosphamide Injection Product Portfolio Table 103. Zydus Cadila Recent Development Table 104. Baxter Company Information Table 105. Baxter Business Overview Table 106. Baxter Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Baxter Cyclophosphamide Injection Product Portfolio Table 108. Baxter Recent Development Table 109. Jiangsu Hengrui Medicine Company Information Table 110. Jiangsu Hengrui Medicine Business Overview Table 111. Jiangsu Hengrui Medicine Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Jiangsu Hengrui Medicine Cyclophosphamide Injection Product Portfolio Table 113. Jiangsu Hengrui Medicine Recent Development Table 114. Pfizer Company Information Table 115. Pfizer Business Overview Table 116. Pfizer Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Pfizer Cyclophosphamide Injection Product Portfolio Table 118. Pfizer Recent Development Table 119. Novartis Company Information Table 120. Novartis Business Overview Table 121. Novartis Cyclophosphamide Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Novartis Cyclophosphamide Injection Product Portfolio Table 123. Novartis Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Cyclophosphamide Injection Distributors List Table 127. Cyclophosphamide Injection Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Cyclophosphamide Injection Product Image Figure 2. Global Cyclophosphamide Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cyclophosphamide Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Cyclophosphamide Injection Sales (2021-2032) & (K Units) Figure 5. Global Cyclophosphamide Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cyclophosphamide Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. High-Dose Image Figure 9. Low-Dose Image Figure 10. Global Cyclophosphamide Injection Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Cyclophosphamide Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Cyclophosphamide Injection Sales Market Share by Type (2021-2032) Figure 13. Global Cyclophosphamide Injection Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Cyclophosphamide Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Cyclophosphamide Injection Revenue Market Share by Type (2021-2032) Figure 16. AL Amyloidosis Image Figure 17. Cancer Image Figure 18. Autoimmune Diseases Image Figure 19. Others Image Figure 20. Global Cyclophosphamide Injection Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Cyclophosphamide Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Cyclophosphamide Injection Sales Market Share by Application (2021-2032) Figure 23. Global Cyclophosphamide Injection Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Cyclophosphamide Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Cyclophosphamide Injection Revenue Market Share by Application (2021-2032) Figure 26. North America Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Cyclophosphamide Injection Sales Market Share by Country (2021-2032) Figure 28. U.S. Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Cyclophosphamide Injection Sales Market Share by Country (2021-2032) Figure 33. Germany Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Cyclophosphamide Injection Sales Market Share by Country (2021-2032) Figure 40. China Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Cyclophosphamide Injection Sales Market Share by Country (2021-2032) Figure 48. Brazil Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Cyclophosphamide Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Cyclophosphamide Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Cyclophosphamide Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Cyclophosphamide Injection Revenue (2021-2032) & (US$ Million) Figure 59. North America Cyclophosphamide Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Cyclophosphamide Injection Revenue (2021-2032) & (US$ Million) Figure 61. Europe Cyclophosphamide Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Cyclophosphamide Injection Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Cyclophosphamide Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Cyclophosphamide Injection Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Cyclophosphamide Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Cyclophosphamide Injection Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Cyclophosphamide Injection Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • High-Dose
  • Low-Dose
Applications
  • AL Amyloidosis
  • Cancer
  • Autoimmune Diseases
  • Others
Companies covered
  • Amneal Pharmaceuticals
  • Athenex
  • Aurobindo Pharma
  • Getwell Oncology
  • GLS Pharma
  • Ingenus
  • NorthStar Rx LLC
  • Zydus Cadila
  • Baxter
  • Jiangsu Hengrui Medicine
  • Pfizer
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cyclophosphamide Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cyclophosphamide Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cyclophosphamide Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cyclophosphamide Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cyclophosphamide Injection Market Dynamics
  1. 2.1 Cyclophosphamide Injection Industry Trends
  2. 2.2 Cyclophosphamide Injection Industry Drivers
  3. 2.3 Cyclophosphamide Injection Industry Opportunities and Challenges
  4. 2.4 Cyclophosphamide Injection Industry Restraints
3 Cyclophosphamide Injection Market by Manufacturers
  1. 3.1 Global Cyclophosphamide Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cyclophosphamide Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cyclophosphamide Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cyclophosphamide Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cyclophosphamide Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cyclophosphamide Injection Manufacturers, Product Type & Application
  7. 3.7 Global Cyclophosphamide Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cyclophosphamide Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cyclophosphamide Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cyclophosphamide Injection Tier 1, Tier 2, and Tier 3
4 Cyclophosphamide Injection Market by Type
  1. 4.1 Cyclophosphamide Injection Type Introduction
  2. 4.1.1 High-Dose
  3. 4.1.2 Low-Dose
  4. 4.2 Global Cyclophosphamide Injection Sales by Type
  5. 4.2.1 Global Cyclophosphamide Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cyclophosphamide Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Cyclophosphamide Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Cyclophosphamide Injection Revenue by Type
  9. 4.3.1 Global Cyclophosphamide Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Cyclophosphamide Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Cyclophosphamide Injection Revenue Market Share by Type (2021-2032)
5 Cyclophosphamide Injection Market by Application
  1. 5.1 Cyclophosphamide Injection Application Introduction
  2. 5.1.1 AL Amyloidosis
  3. 5.1.2 Cancer
  4. 5.1.3 Autoimmune Diseases
  5. 5.1.4 Others
  6. 5.2 Global Cyclophosphamide Injection Sales by Application
  7. 5.2.1 Global Cyclophosphamide Injection Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cyclophosphamide Injection Sales by Application (2021-2032)
  9. 5.2.3 Global Cyclophosphamide Injection Sales Market Share by Application (2021-2032)
  10. 5.3 Global Cyclophosphamide Injection Revenue by Application
  11. 5.3.1 Global Cyclophosphamide Injection Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Cyclophosphamide Injection Revenue by Application (2021-2032)
  13. 5.3.3 Global Cyclophosphamide Injection Revenue Market Share by Application (2021-2032)
6 Global Cyclophosphamide Injection Sales by Region
  1. 6.1 Global Cyclophosphamide Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cyclophosphamide Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Cyclophosphamide Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Cyclophosphamide Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cyclophosphamide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cyclophosphamide Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cyclophosphamide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cyclophosphamide Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cyclophosphamide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cyclophosphamide Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cyclophosphamide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cyclophosphamide Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cyclophosphamide Injection Revenue by Region
  1. 7.1 Global Cyclophosphamide Injection Revenue by Region
  2. 7.1.1 Global Cyclophosphamide Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cyclophosphamide Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Cyclophosphamide Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Cyclophosphamide Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cyclophosphamide Injection Revenue (2021-2032)
  8. 7.2.2 North America Cyclophosphamide Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cyclophosphamide Injection Revenue (2021-2032)
  11. 7.3.2 Europe Cyclophosphamide Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cyclophosphamide Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cyclophosphamide Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cyclophosphamide Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cyclophosphamide Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amneal Pharmaceuticals
  2. 8.1.1 Amneal Pharmaceuticals Company Information
  3. 8.1.2 Amneal Pharmaceuticals Business Overview
  4. 8.1.3 Amneal Pharmaceuticals Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amneal Pharmaceuticals Cyclophosphamide Injection Product Portfolio
  6. 8.1.5 Amneal Pharmaceuticals Recent Developments
  7. 8.2 Athenex
  8. 8.2.1 Athenex Company Information
  9. 8.2.2 Athenex Business Overview
  10. 8.2.3 Athenex Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Athenex Cyclophosphamide Injection Product Portfolio
  12. 8.2.5 Athenex Recent Developments
  13. 8.3 Aurobindo Pharma
  14. 8.3.1 Aurobindo Pharma Company Information
  15. 8.3.2 Aurobindo Pharma Business Overview
  16. 8.3.3 Aurobindo Pharma Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Aurobindo Pharma Cyclophosphamide Injection Product Portfolio
  18. 8.3.5 Aurobindo Pharma Recent Developments
  19. 8.4 Getwell Oncology
  20. 8.4.1 Getwell Oncology Company Information
  21. 8.4.2 Getwell Oncology Business Overview
  22. 8.4.3 Getwell Oncology Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Getwell Oncology Cyclophosphamide Injection Product Portfolio
  24. 8.4.5 Getwell Oncology Recent Developments
  25. 8.5 GLS Pharma
  26. 8.5.1 GLS Pharma Company Information
  27. 8.5.2 GLS Pharma Business Overview
  28. 8.5.3 GLS Pharma Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GLS Pharma Cyclophosphamide Injection Product Portfolio
  30. 8.5.5 GLS Pharma Recent Developments
  31. 8.6 Ingenus
  32. 8.6.1 Ingenus Company Information
  33. 8.6.2 Ingenus Business Overview
  34. 8.6.3 Ingenus Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ingenus Cyclophosphamide Injection Product Portfolio
  36. 8.6.5 Ingenus Recent Developments
  37. 8.7 NorthStar Rx LLC
  38. 8.7.1 NorthStar Rx LLC Company Information
  39. 8.7.2 NorthStar Rx LLC Business Overview
  40. 8.7.3 NorthStar Rx LLC Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NorthStar Rx LLC Cyclophosphamide Injection Product Portfolio
  42. 8.7.5 NorthStar Rx LLC Recent Developments
  43. 8.8 Zydus Cadila
  44. 8.8.1 Zydus Cadila Company Information
  45. 8.8.2 Zydus Cadila Business Overview
  46. 8.8.3 Zydus Cadila Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Zydus Cadila Cyclophosphamide Injection Product Portfolio
  48. 8.8.5 Zydus Cadila Recent Developments
  49. 8.9 Baxter
  50. 8.9.1 Baxter Company Information
  51. 8.9.2 Baxter Business Overview
  52. 8.9.3 Baxter Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Baxter Cyclophosphamide Injection Product Portfolio
  54. 8.9.5 Baxter Recent Developments
  55. 8.10 Jiangsu Hengrui Medicine
  56. 8.10.1 Jiangsu Hengrui Medicine Company Information
  57. 8.10.2 Jiangsu Hengrui Medicine Business Overview
  58. 8.10.3 Jiangsu Hengrui Medicine Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Hengrui Medicine Cyclophosphamide Injection Product Portfolio
  60. 8.10.5 Jiangsu Hengrui Medicine Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Cyclophosphamide Injection Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Novartis
  68. 8.12.1 Novartis Company Information
  69. 8.12.2 Novartis Business Overview
  70. 8.12.3 Novartis Cyclophosphamide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novartis Cyclophosphamide Injection Product Portfolio
  72. 8.12.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cyclophosphamide Injection Value Chain Analysis
  2. 9.1.1 Cyclophosphamide Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cyclophosphamide Injection Production Mode & Process
  6. 9.2 Cyclophosphamide Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cyclophosphamide Injection Distributors
  9. 9.2.3 Cyclophosphamide Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst